This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Myovant Sciences Crecimiento futuro
Future controles de criterios 5/6
Información clave
59.0%
Tasa de crecimiento de los beneficios
60.3%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 24.8% |
| Tasa de crecimiento de los ingresos | 27.6% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 10 Mar 2023 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M
Jan 26Not The Buyout Offer That Myovant Shareholders Hoped For
Oct 25Myovant Sciences rejects Sumitovant Biopharma's $22.75/share takeover offer
Oct 03Women Can Thank Pfizer And Myovant For MYFEMBREE
Sep 20Myovant Sciences: Regulatory Overhang Cleared
Aug 29Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication
Aug 09Myovant stock gains ~6% after hours on Q1 revenue jump
Jul 27Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree
Jul 18Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher
Apr 28
Myovant: Poised To Overcome Regulatory Issues
Apr 26Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels
Apr 13Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play
Mar 26Myovant: Catalysts Powering More Upside
Jan 02Myovant Sciences: Becoming A Blockbuster
Jun 02Myovant Sciences rises on FDA approval for relugolix
May 26Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates
May 14Why The Misunderstood Pfizer Deal Makes Myovant A Great Low-Risk Investment
May 09New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)
Feb 17Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates
Feb 13Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher
Jan 12Myovant cut to neutral at Goldman Sachs on ‘lack of driving catalysts’
Jan 06Myovant Sciences announces distribution of ORGOVYX in the U.S.
Jan 05Myovant Sciences gains 22% on relugolix deal with Pfizer
Dec 28Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?
Dec 23
Myovant Sciences’ FDA win leads to Bullish views at Baird
Dec 21Myovant Sciences scores FDA approval for Orgovyx in prostate cancer
Dec 18Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price Gain
Nov 18Myovant Sciences: More Than Meets The Eye
Nov 12The Sell-Off In Myovant Is Unjustified By Fundamentals
Nov 09Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 3/31/2025 | 618 | -74 | N/A | N/A | 2 |
| 3/31/2024 | 555 | -76 | N/A | N/A | 3 |
| 3/31/2023 | 418 | -153 | N/A | N/A | 2 |
| 12/31/2022 | 379 | -184 | -271 | -270 | N/A |
| 9/30/2022 | 333 | -190 | -260 | -259 | N/A |
| 6/30/2022 | 306 | -166 | -232 | -231 | N/A |
| 3/31/2022 | 231 | -206 | -270 | -269 | N/A |
| 12/31/2021 | 198 | -228 | -263 | -261 | N/A |
| 9/30/2021 | 145 | -238 | 403 | 405 | N/A |
| 6/30/2021 | 67 | -284 | 318 | 319 | N/A |
| 3/31/2021 | 59 | -255 | 369 | 371 | N/A |
| 12/31/2020 | 35 | -239 | 443 | 444 | N/A |
| 9/30/2020 | 33 | -250 | -198 | -197 | N/A |
| 6/30/2020 | 33 | -254 | -217 | -216 | N/A |
| 3/31/2020 | N/A | -289 | -222 | -221 | N/A |
| 12/31/2019 | N/A | -299 | -256 | -255 | N/A |
| 9/30/2019 | N/A | -284 | -252 | -250 | N/A |
| 6/30/2019 | N/A | -279 | -247 | -246 | N/A |
| 3/31/2019 | N/A | -274 | -225 | -224 | N/A |
| 12/31/2018 | N/A | -247 | -207 | -206 | N/A |
| 9/30/2018 | N/A | -218 | -176 | -175 | N/A |
| 6/30/2018 | N/A | -182 | -136 | -135 | N/A |
| 3/31/2018 | N/A | -143 | -118 | -117 | N/A |
| 12/31/2017 | N/A | -117 | -94 | -93 | N/A |
| 9/30/2017 | N/A | -83 | -70 | -69 | N/A |
| 6/30/2017 | N/A | -88 | -46 | -45 | N/A |
| 3/31/2017 | N/A | -83 | -19 | -18 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: MYOV is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).
Beneficios vs. Mercado: MYOV is forecast to become profitable over the next 3 years, which is considered above average market growth.
Beneficios de alto crecimiento: MYOV is expected to become profitable in the next 3 years.
Ingresos vs. Mercado: MYOV's revenue (27.6% per year) is forecast to grow faster than the US market (6.9% per year).
Ingresos de alto crecimiento: MYOV's revenue (27.6% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if MYOV's Return on Equity is forecast to be high in 3 years time